Blastic phase of chronic myelogenous leukemia

@article{Esfahani2006BlasticPO,
  title={Blastic phase of chronic myelogenous leukemia},
  author={Merat Karbasian Esfahani and E. L. Morris and J. Dutcher and P. Wiernik},
  journal={Current Treatment Options in Oncology},
  year={2006},
  volume={7},
  pages={189-199}
}
  • Merat Karbasian Esfahani, E. L. Morris, +1 author P. Wiernik
  • Published 2006
  • Medicine
  • Current Treatment Options in Oncology
    • Opinion statementChronic myelogenous leukemia (CML), also known as chronic myelocytic or chronic myeloid leukemia, is a clonal disorder of hematopoiesis that arises in a hematopoietic stem cell or early progenitor cell. This is characterized by the dysregulated production of mature non-lymphoid cells with normal differentiation. Eventually, in spite of the term chronic, there is progression to acute leukemia, usually of the myeloid variety, which is highly resistant to current therapies… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    40 Citations
    Highly Influential Citations
    2
    Background Citations
    15
    Methods Citations
    1
    40 Citations
    Citation Type

    Citation Type

    Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase
    • 1
    • PDF
    Unrelated Allogeneic Stem Cell Transplantation in a Patient with Chronic Myeloid Leukemia in Blast Crisis
    • PDF
    CML with Megakaryocytic Blast Crisis: Report of 3 Cases
    Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    • 31
    Monocytic crisis of chronic myeloid leukemia in the era of tyrosine kinase inhibitor.
    • 4
    • PDF
    Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
    • 6
    • PDF
    Case Study Monocytic Crisis of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor
    Chronic Myeloid Leukemia with Extramedullary Blast Crisis: Two Unusual Sites with Review of Literature
    • 20
    Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey.
    • 8
    SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA

    References

    SHOWING 1-10 OF 54 REFERENCES
    Accelerated and blastic phase of chronic myeloid leukemia
    • 11
    Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    • 1,161
    • PDF
    Chronic Myelogenous Leukemia: Biology and Therapy
    • 330
    Pathobiology of lymphoid and myeloid blast crisis and management issues.
    • R. Ilaria
    • Medicine
    • Hematology. American Society of Hematology. Education Program
    • 2005
    • 44
    • PDF
    Blastic phase of chronic myelogenous leukemia.
    • 1
    Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
    • 280
    The biology of CML blast crisis.
    • 572
    • PDF
    Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies
    • 71
    A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
    • 544
    • PDF
    The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
    • 104
    • PDF